Abstract
With the incidence of sleeping sickness in decline and genuine progress being made towards the WHO goal of eliminating sleeping sickness as a major public health concern, this is a good moment to evaluate the drugs that ‘got the job done’: their development, their limitations and the resistance that the parasites developed against them. This retrospective looks back on the remarkable story of chemotherapy against trypanosomiasis, a story that goes back to the very origins and conception of chemotherapy in the first years of the 20 century and is still not finished today.
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Immunology and Microbiology
Reference186 articles.
1. Fexinidazole for the treatment of human African trypanosomiasis
2. Treatment options for second-stage gambiense human African trypanosomiasis
3. R&D Portfolio Update February 2019: DNDi Sleeping Sickness Programmewww.dndi.org/2019/media-centre/news-views-stories/news/sleepingsickness_rnd_status_2019/
4. SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis
5. Mort par hypoglycémie dans les trypanosomiases aiguës;Dubois;CR Soc. Biol.,1928
Cited by
94 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献